These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 29397979)

  • 1. Extending the limits of size exclusion chromatography: Simultaneous separation of free payloads and related species from antibody drug conjugates and their aggregates.
    Goyon A; Sciascera L; Clarke A; Guillarme D; Pell R
    J Chromatogr A; 2018 Mar; 1539():19-29. PubMed ID: 29397979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intact quantitation of cysteine-conjugated antibody-drug conjugates using native mass spectrometry.
    Li Y; Wang Y; Shenoy VM; Niu S; Jenkins GJ; Sarvaiya H
    Rapid Commun Mass Spectrom; 2024 Aug; 38(15):e9774. PubMed ID: 38812280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two-Dimensional SEC-SEC-UV-MALS-dRI Workflow for Streamlined Analysis and Characterization of Biopharmaceuticals.
    Barrientos RC; Singh AN; Ukaegbu O; Hemida M; Wang H; Haidar Ahmad I; Hu H; Dunn ZD; Appiah-Amponsah E; Regalado EL
    Anal Chem; 2024 Mar; 96(12):4960-4968. PubMed ID: 38436624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring of the disulfide scrambled species by mixed-mode SEC-HPLC during the purification of a bispecific antibody.
    Tian M; Li D; Hu L; Dong W; Wang T; Li Y
    Protein Expr Purif; 2024 Jul; ():106544. PubMed ID: 38972616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Online hyphenation of size-exclusion chromatography and gas-phase electrophoresis facilitates the characterization of protein aggregates.
    Weiss VU; Denderz N; Allmaier G; Marchetti-Deschmann M
    Electrophoresis; 2021 Jun; 42(11):1202-1208. PubMed ID: 33651392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing Messenger RNA Analysis Using Ultra-Wide Pore Size Exclusion Chromatography Columns.
    D'Atri V; Lardeux H; Goyon A; Imiołek M; Fekete S; Lauber M; Zhang K; Guillarme D
    Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Three Complementary Analytical Techniques for the Evaluation of the Biosimilar Comparability of a Monoclonal Antibody and an Fc-Fusion Protein.
    Demelenne A; Ben Yahia A; Lempereur D; Crommen J; Servais AC; Fradi I; Fillet M
    Front Chem; 2021; 9():782099. PubMed ID: 34938718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of antibody surface properties and selection of a diverse subset for development of a generic size-exclusion chromatography method.
    Reinau ME; Åsberg D
    J Chromatogr A; 2024 Feb; 1716():464652. PubMed ID: 38241898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Online Coupling of Size Exclusion Chromatography to Capillary Enhanced Raman Spectroscopy for the Analysis of Proteins and Biopharmaceutical Drug Products.
    Thissen J; Klassen MD; Constantinidis P; Hacker MC; Breitkreutz J; Teutenberg T; Fischer B
    Anal Chem; 2023 Dec; 95(48):17868-17877. PubMed ID: 38050672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Separation of Plasmid DNA Topological Forms, Messenger RNA, and Lipid Nanoparticle Aggregates Using an Ultrawide Pore Size Exclusion Chromatography Column.
    Goyon A; Tang S; Fekete S; Nguyen D; Hofmann K; Wang S; Shatz-Binder W; Fernandez KI; Hecht ES; Lauber M; Zhang K
    Anal Chem; 2023 Oct; 95(40):15017-15024. PubMed ID: 37747361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact on Quality during In-Use Preparation of an Antibody Drug Conjugate with Eight Different Closed System Transfer Device Brands.
    Sorret L; Tan WH; Voss S; Favrod P; Chalus P; Winzer M
    AAPS J; 2024 May; 26(3):61. PubMed ID: 38750400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Size-Exclusion Chromatography for the Analysis of Protein Biotherapeutics and their Aggregates.
    Hong P; Koza S; Bouvier ES
    J Liq Chromatogr Relat Technol; 2012 Nov; 35(20):2923-2950. PubMed ID: 23378719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-Drug Conjugates for Cancer Treatment.
    Lambert JM; Berkenblit A
    Annu Rev Med; 2018 Jan; 69():191-207. PubMed ID: 29414262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MI130004, a Novel Antibody-Drug Conjugate Combining Trastuzumab with a Molecule of Marine Origin, Shows Outstanding
    Avilés P; Domínguez JM; Guillén MJ; Muñoz-Alonso MJ; Mateo C; Rodriguez-Acebes R; Molina-Guijarro JM; Francesch A; Martínez-Leal JF; Munt S; Galmarini CM; Cuevas C
    Mol Cancer Ther; 2018 Apr; 17(4):786-794. PubMed ID: 29440297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of disulfide bond isoforms on drug conjugation sites in cysteine-linked IgG2 antibody-drug conjugates.
    Liu-Shin L; Fung A; Malhotra A; Ratnaswamy G
    MAbs; 2018; 10(4):583-595. PubMed ID: 29436897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-Throughput Cysteine Scanning To Identify Stable Antibody Conjugation Sites for Maleimide- and Disulfide-Based Linkers.
    Ohri R; Bhakta S; Fourie-O'Donohue A; Dela Cruz-Chuh J; Tsai SP; Cook R; Wei B; Ng C; Wong AW; Bos AB; Farahi F; Bhakta J; Pillow TH; Raab H; Vandlen R; Polakis P; Liu Y; Erickson H; Junutula JR; Kozak KR
    Bioconjug Chem; 2018 Feb; 29(2):473-485. PubMed ID: 29425028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leveraging Formylglycine-Generating Enzyme for Production of Site-Specifically Modified Bioconjugates.
    Barfield RM; Rabuka D
    Methods Mol Biol; 2018; 1728():3-16. PubMed ID: 29404988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study.
    Banerjee S; Oza AM; Birrer MJ; Hamilton EP; Hasan J; Leary A; Moore KN; Mackowiak-Matejczyk B; Pikiel J; Ray-Coquard I; Trask P; Lin K; Schuth E; Vaze A; Choi Y; Marsters JC; Maslyar DJ; Lemahieu V; Wang Y; Humke EW; Liu JF
    Ann Oncol; 2018 Apr; 29(4):917-923. PubMed ID: 29401246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishing in vitro-in vivo correlation for antibody drug conjugate efficacy: a PK/PD modeling approach.
    Shah DK; Loganzo F; Haddish-Berhane N; Musto S; Wald HS; Barletta F; Lucas J; Clark T; Hansel S; Betts A
    J Pharmacokinet Pharmacodyn; 2018 Apr; 45(2):339-349. PubMed ID: 29423862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioconjugation through Mesitylene Thiol Alkylation.
    Ramos-Tomillero I; Perez-Chacon G; Somovilla-Crespo B; Sanchez-Madrid F; Domínguez JM; Cuevas C; Zapata JM; Rodríguez H; Albericio F
    Bioconjug Chem; 2018 Apr; 29(4):1199-1208. PubMed ID: 29433317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.